HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Temporal trends, risk factors and outcomes of infections due to extended-spectrum β-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018.

AbstractBACKGROUND:
The burden of antimicrobial resistance is high in solid organ transplant (SOT) recipients. Among Swiss SOT recipients, we assessed temporal trends of ESBL-producing Enterobacterales (ESBL-E), identified risk factors for ESBL-E, and assessed the impact of resistance on patient outcome.
METHODS:
Data from the Swiss Transplant Cohort Study (STCS), a nationwide prospective cohort of SOT-recipients, were analysed. Temporal trends were described for ESBL-detection among Escherichia coli and non-Escherichia coli. In a nested case-control study, cases with ESBL-E infection were 1:1 matched (by time since transplantation, organ transplant, pathogen) to controls infected with non-ESBL-E. Factors associated with resistance and with unfavourable 30-day outcome (death, infection relapse, graft loss) were assessed.
RESULTS:
From 2012 to 2018, we identified 1'212 infection episodes caused by Enterobacterales in 1'074 patients, thereof 11.4% (138/1'212) caused by ESBL-E. The proportion of ESBL-production among Escherichia coli remained stable over time (p = 0.93) but increased for non-E. coli (p = 0.02) Enterobacterales. In the case-control study (n = 102), antibiotic pre-treatment was independently associated with ESBL-production (aOR = 2.6, 95%-CI: 1.0-6.8, p = 0.046). Unfavourable outcome occurred in 24/51 (47%) cases and 9/51 (18%) controls (p = 0.003). Appropriate empiric antibiotic therapy was the only modifiable factor associated with unfavourable outcome.
CONCLUSIONS:
In Swiss SOT-recipients, proportion of infections with ESBL-producing non-E. coli Enterobacterales increased in recent years. Antibiotic pre-treatment represents a risk factor for ESBL-E. Improving appropriateness of empiric antibiotic treatment might be an important measure to reduce unfavourable outcome, which was observed in almost half of SOT-recipients with ESBL-E infections.
AuthorsPhilipp Kohler, Aline Wolfensberger, Susanne Stampf, Andreas Brönnimann, Katia Boggian, Christian van Delden, Melody Favre, Cédric Hirzel, Nina Khanna, Stefan P Kuster, Oriol Manuel, Dionysios Neofytos, Silvio Ragozzino, Peter W Schreiber, Laura Walti, Nicolas J Mueller, Swiss Transplant Cohort Study
JournalAntimicrobial resistance and infection control (Antimicrob Resist Infect Control) Vol. 10 Issue 1 Pg. 50 (03 07 2021) ISSN: 2047-2994 [Electronic] England
PMID33678189 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • beta-Lactamases
Topics
  • Adult
  • Aged
  • Anti-Bacterial Agents (administration & dosage)
  • Case-Control Studies
  • Drug Resistance, Bacterial
  • Enterobacteriaceae
  • Enterobacteriaceae Infections (complications, mortality)
  • Escherichia coli Infections
  • Female
  • Graft Rejection (microbiology)
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation
  • Prospective Studies
  • Risk Factors
  • Switzerland
  • Transplant Recipients
  • beta-Lactamases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: